Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...
Read Full NewsScreening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Combination therapies remain key as multiple agents for melasma hit the market.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.
A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
1.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
2.
Certain surgical gestures during prostate removal linked to better sexual function recovery
3.
Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.
4.
Many patients learn they could have cancer in the emergency department
5.
Scientists discover the 'roadmap' that aggressive cancer uses to spread
1.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
2.
Mastering Prostate Cancer Care: CME, Certification, Digital Tools, and Evidence-Based Strategies
3.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
4.
Revolutionizing Cancer Treatment: ESMO's Updated Recommendations for Tumour NGS
5.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
5.
A New Era in Managing Cancer-Associated Thrombosis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge